CAPTRUST Financial Advisors
SRPT icon

CAPTRUST Financial Advisors’s Sarepta Therapeutics SRPT Stock Holding History

CAPTRUST Financial Advisors’s Portfolio SRPT Stock Details SRPT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$391K Sell
21,745
-18,396
-46% -$348K ﹤0.01% 2365
2026
Q1 		$873K Sell
40,141
-8,611
-18% -$167K ﹤0.01% 1691
2025
Q4 		$1.05M Buy
48,752
+35,517
+268% +$749K ﹤0.01% 1477
2025
Q3 		$255K Buy
+13,235
New +$236K ﹤0.01% 2285
2025
Q1 		– Sell
-4,468
Closed -$543K – 2450
2024
Q4 		$543K Buy
4,468
+597
+15% +$73.2K ﹤0.01% 1564
2024
Q3 		$483K Buy
3,871
+511
+15% +$70.6K ﹤0.01% 1591
2024
Q2 		$531K Buy
3,360
+938
+39% +$120K ﹤0.01% 1469
2024
Q1 		$314K Sell
2,422
-2,448
-50% -$300K ﹤0.01% 1750
2023
Q4 		$470K Sell
4,870
-793
-14% -$76.1K ﹤0.01% 1777
2023
Q3 		$686K Sell
5,663
-235
-4% -$26.6K ﹤0.01% 1431
2023
Q2 		$675K Sell
5,898
-826
-12% -$107K ﹤0.01% 1455
2023
Q1 		$927K Buy
6,724
+783
+13% +$102K ﹤0.01% 1082
2022
Q4 		$770K Buy
5,941
+2,153
+57% +$249K ﹤0.01% 1110
2022
Q3 		$419K Buy
3,788
+317
+9% +$32K ﹤0.01% 1331
2022
Q2 		$260K Buy
3,471
+44
+1% +$3.24K ﹤0.01% 1511
2022
Q1 		$268K Buy
3,427
+77
+2% +$5.9K ﹤0.01% 1523
2021
Q4 		$302K Sell
3,350
-2,627
-44% -$225K ﹤0.01% 1381
2021
Q3 		$553K Sell
5,977
-665
-10% -$51.2K ﹤0.01% 989
2021
Q2 		$516K Sell
6,642
-101
-1% -$7.66K ﹤0.01% 975
2021
Q1 		$503K Sell
6,743
-142
-2% -$13.1K 0.01% 949
2020
Q4 		$1.17M Sell
6,885
-70
-1% -$10.4K 0.02% 567
2020
Q3 		$984K Sell
6,955
-215
-3% -$32.7K 0.02% 516
2020
Q2 		$1.19M Sell
7,170
-4,145
-37% -$564K 0.02% 454
2020
Q1 		$1.05M Sell
11,315
-765
-6% -$87.4K 0.02% 408
2019
Q4 		$1.56M Buy
+12,080
New +$1.22M 0.02% 417

Other funds holding SRPT

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
First Trust Advisors
First Trust Advisors Wheaton, Illinois $170B AUM 46.21% 1-Year Est. Return
AQR Capital Management
AQR Capital Management Greenwich, Connecticut $287B AUM 42.33% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
EAM
Erste Asset Management Vienna, Austria $12.9B AUM 52.69% 1-Year Est. Return
Marshall Wace
Marshall Wace London, United Kingdom $127B AUM 46.06% 1-Year Est. Return

CAPTRUST Financial Advisors's SRPT Position: Q2 2026 in Review

CAPTRUST Financial Advisors reduced its Sarepta Therapeutics (SRPT) stake by 46% in Q2 2026, selling an estimated $348K and leaving 21,745 shares worth $391K. The position accounts for ﹤0.01% of the portfolio, ranked #2365.

CAPTRUST Financial Advisors first reported a position in SRPT in Q4 2019 and has held it in 25 quarters since. The position peaked at $1.56M in Q4 2019. 324 funds tracked by Wall St. Rank hold SRPT as of Q2 2026.

  • CAPTRUST Financial Advisors held 21,745 shares of Sarepta Therapeutics worth $391K as of Q2 2026.
  • CAPTRUST Financial Advisors sold 18,396 Sarepta Therapeutics shares in Q2 2026, an estimated $348K.
  • Sarepta Therapeutics made up ﹤0.01% of CAPTRUST Financial Advisors's portfolio in Q2 2026, its #2365 holding.
  • CAPTRUST Financial Advisors first reported a position in Sarepta Therapeutics in Q4 2019 and has held it in 25 quarters since.
  • CAPTRUST Financial Advisors's Sarepta Therapeutics position peaked at $1.56M in Q4 2019.
  • 324 funds tracked by Wall St. Rank held Sarepta Therapeutics as of Q2 2026.

Based on CAPTRUST Financial Advisors's 13F filing for Q2 2026, filed 13 Aug 2026.